Clinical Trial: Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i

U.S., May 15 -- ClinicalTrials.gov registry received information related to the study (NCT07586371) titled 'Proteinuria in Normotensive Diabetic Patients: ARBs Alone or in Combination of SGLT2i' on May 07.

Brief Summary: Proteinuria is an early marker of diabetic kidney disease and predicts progression to chronic kidney disease and cardiovascular complications. ARBs are proven to reduce proteinuria and slow renal damage, even in normotensive diabetic patients. SGLT2 inhibitors have recently shown additional reno-protective effects, including further reduction in proteinuria and slowing of disease progression. Combining ARBs with SGLT2 inhibitors may provide additive or synergistic benefits. However, there is limited data comparing ARBs alo...